ECSP12011629A - Fulvestrant en una dosis de 500 mg para el tratamiento del cáncer de mama avanzado - Google Patents

Fulvestrant en una dosis de 500 mg para el tratamiento del cáncer de mama avanzado

Info

Publication number
ECSP12011629A
ECSP12011629A EC2012011629A ECSP12011629A ECSP12011629A EC SP12011629 A ECSP12011629 A EC SP12011629A EC 2012011629 A EC2012011629 A EC 2012011629A EC SP12011629 A ECSP12011629 A EC SP12011629A EC SP12011629 A ECSP12011629 A EC SP12011629A
Authority
EC
Ecuador
Prior art keywords
fulvestrant
dose
treatment
breast cancer
advanced breast
Prior art date
Application number
EC2012011629A
Other languages
English (en)
Inventor
Isaiah William Dimery
Alan Webster
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011629(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP12011629A publication Critical patent/ECSP12011629A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a fulvestrant en una dosis de 500 mg para utilizar en el tratamiento de una mujer posmenopáusica con un cáncer de mama avanzado que ha sufrido un avance o una recidiva durante la terapia endocrina.
EC2012011629A 2009-07-27 2012-01-27 Fulvestrant en una dosis de 500 mg para el tratamiento del cáncer de mama avanzado ECSP12011629A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0912999.0A GB0912999D0 (en) 2009-07-27 2009-07-27 Method-803

Publications (1)

Publication Number Publication Date
ECSP12011629A true ECSP12011629A (es) 2012-02-29

Family

ID=41066853

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2012011629A ECSP12011629A (es) 2009-07-27 2012-01-27 Fulvestrant en una dosis de 500 mg para el tratamiento del cáncer de mama avanzado

Country Status (36)

Country Link
US (1) US20120214778A1 (es)
EP (1) EP2459199A1 (es)
JP (1) JP2013500324A (es)
KR (1) KR20120042843A (es)
AT (1) AT510868A2 (es)
AU (1) AU2010277373A1 (es)
BG (1) BG111123A (es)
BR (1) BR112012001837A2 (es)
CA (1) CA2768286A1 (es)
CL (1) CL2012000226A1 (es)
CZ (1) CZ201235A3 (es)
DE (1) DE112010003084T5 (es)
DK (1) DK201270089A (es)
EA (1) EA201200190A1 (es)
EC (1) ECSP12011629A (es)
EE (1) EE201200003A (es)
ES (1) ES2393323A1 (es)
FI (1) FI20125207L (es)
GB (2) GB0912999D0 (es)
HR (1) HRP20120084A2 (es)
HU (1) HUP1200203A3 (es)
IL (1) IL217527A0 (es)
IS (1) IS8994A (es)
LT (1) LT5953B (es)
MX (1) MX2012001282A (es)
NO (1) NO20120147A1 (es)
PE (1) PE20121177A1 (es)
PL (1) PL399129A1 (es)
RO (1) RO128705A2 (es)
RS (1) RS20120022A1 (es)
SE (1) SE1250155A1 (es)
SG (1) SG177586A1 (es)
SK (1) SK500052012A3 (es)
TR (1) TR201200950T1 (es)
WO (1) WO2011012885A1 (es)
ZA (1) ZA201201406B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CN106456776A (zh) * 2014-05-21 2017-02-22 豪夫迈·罗氏有限公司 用PI3K抑制剂Pictilisib治疗PR阳性腔性A乳腺癌的方法
US20190147986A1 (en) * 2016-05-17 2019-05-16 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies
US11642356B2 (en) 2016-10-21 2023-05-09 Crescita Therapeutics Inc. Pharmaceutical compositions
WO2018106444A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
KR102267378B1 (ko) * 2019-09-10 2021-06-21 가천대학교 산학협력단 C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
US20120214778A1 (en) 2012-08-23
EA201200190A1 (ru) 2012-08-30
IS8994A (is) 2012-02-24
TR201200950T1 (tr) 2012-09-21
NO20120147A1 (no) 2012-04-03
AT510868A2 (de) 2012-07-15
FI20125207L (fi) 2012-02-23
ZA201201406B (en) 2013-08-28
AU2010277373A1 (en) 2012-02-09
PE20121177A1 (es) 2012-09-23
HRP20120084A2 (hr) 2012-04-30
KR20120042843A (ko) 2012-05-03
GB0912999D0 (en) 2009-09-02
WO2011012885A9 (en) 2011-03-24
RO128705A2 (ro) 2013-08-30
GB201201486D0 (en) 2012-03-14
IL217527A0 (en) 2012-02-29
LT2012006A (lt) 2013-03-25
HUP1200203A3 (en) 2012-12-28
SG177586A1 (en) 2012-02-28
LT5953B (lt) 2013-07-25
JP2013500324A (ja) 2013-01-07
ES2393323A1 (es) 2012-12-20
CL2012000226A1 (es) 2012-08-31
EP2459199A1 (en) 2012-06-06
CA2768286A1 (en) 2011-02-03
HUP1200203A1 (en) 2012-09-28
BR112012001837A2 (pt) 2016-03-15
DK201270089A (en) 2012-02-24
WO2011012885A1 (en) 2011-02-03
EE201200003A (et) 2012-04-16
SE1250155A1 (sv) 2012-02-22
SK500052012A3 (sk) 2012-04-03
GB2484050A (en) 2012-03-28
DE112010003084T5 (de) 2012-09-06
RS20120022A1 (en) 2012-10-31
MX2012001282A (es) 2012-06-12
PL399129A1 (pl) 2012-11-19
BG111123A (bg) 2012-10-31
CZ201235A3 (cs) 2012-06-27

Similar Documents

Publication Publication Date Title
ECSP12011629A (es) Fulvestrant en una dosis de 500 mg para el tratamiento del cáncer de mama avanzado
DOP2010000141A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
CO6630103A2 (es) Fitocanabinoides en el tratamiento de cáncer
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
ECSP12011943A (es) Antagonistas de espiro-oxindol de mdm2
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CO6450651A2 (es) Terapia complementaria contra el cancer
GT201200123A (es) Nuevo uso antitumoral de cabazitaxel
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
MX2016015161A (es) Metodos de tratamiento de cancer de mama luminal a positivo para pr con inhibidor de pi3k, pictilisib.
MX2015014344A (es) Terapia contra el cancer.
UY33740A (es) Método para tratar el cáncer de mama y cáncer de ovarios
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
CL2020002637A1 (es) Métodos de tratamiento de cáncer.
NI201100228A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
TH156277A (th) การรักษามะเร็งด้วยตัวยับยั้ง tor ไคเนส
MY174794A (en) Anticancer composition
AR098781A1 (es) Compuestos peptidomiméticos y conjugados anticuerpos-droga de los mismos